Current Neuro-Oncology

Volume 24 Number 10
31 May 2022

Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 10, 31 May

Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB.
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
CNS Oncol. 2022 May 16;11(2):CNS87∟. doi: 10.2217/cns-2022-0005∟. PMID: 35575067∟. Interventional study. ˍ

*

Pauletto G, Nilo A, Lettieri C, Verriello L, Tomasino B, Gigli GL, Skrap M, Ius T.
Pre- and Post-surgical Poor Seizure Control as Hallmark of Malignant Progression in Patients With Glioma?
Front Neurol. 2022 May 16;13:890857∟. doi: 10.3389/fneur.2022.890857∟. PMID: 35651351∟. Observational study. ˍ

*

Qing Z, Xiaoai K, Caiqiang X, Shenglin L, Xiaoyu H, Bin Z, Junlin Z.
Nomogram for predicting early recurrence in patients with high-grade gliomas.
World Neurosurg. 2022 May 16;164:e619-e628∟. doi: 10.1016/j.wneu.2022.05.039∟. PMID: 35589036∟. Observational study˰ ˍ

Breen WG, Youland RS, Giri S, Jacobson SB, Pafundi DH, Brown PD, Hunt CH, Mahajan A, Ruff MW, Kizilbash SH, Uhm JH, Routman DM, Jones JE, Brinkmann DH, Laack NN.
Initial results of a phase II trial of ¹⁸F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.
J Neurooncol. 2022 May 18∟. doi: 10.1007/s11060-022-04011-w∟. PMID: 35583721∟. Interventional study˰ ˍ

*

Chi X, Wang Y, Li C, Huang X, Gao H, Zhang Y, Ji N.
Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma.
Front Oncol. 2022 May 18;12:877190∟. doi: 10.3389/fonc.2022.877190∟. PMID: 35664765∟. Observational study. ˍ

*

Liu CA, Harn HJ, Chen KP, Lee JH, Lin SZ, Chiu TL.
Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM.
J Oncol. 2022 May 18;2022:3236058∟. doi: 10.1155/2022/3236058∟. PMID: 35646111∟. Case report. ˍ

Mueller S, Cooney T, Yang X, Pal S, Ermoian R, Gajjar A, Liu X, Prem K, Minard CG, Reid JM, Nelson M, Haas-Kogan D, Fox E, Weigel BJ.
Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study.
Neurooncol Adv. 2022 May 20;4(1):vdac073∟. doi: 10.1093/noajnl/vdac073∟. PMID: 35733515∟. Interventional study. ˍ

*

Valipour E, Ranjbar FE, Mousavi M, Ai J, Malekshahi ZV, Mokhberian N, Taghdiri-Nooshabadi Z, Khanmohammadi M, Nooshabadi VT.
The anti-angiogenic effect of atorvastatin loaded exosomes on glioblastoma tumor cells: An in vitro 3D culture model.
Microvasc Res. 2022 May 21, 2022:104385∟. doi: 10.1016/j.mvr.2022.104385∟. PMID: 35609635∟. Laboratory investigation˰ ˍ

Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M.
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Neurol Res Pract. 2022 May 23;4(1):20∟. doi: 10.1186/s42466-022-00184-x∟. PMID: 35599302∟. Interventional study. ˍ

Shi X, Li H, Xu Y, Nyalali AMK, Li F.
The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients.
Neurol Sci. 2022 May 23;43(9):5523-5531∟. doi: 10.1007/s10072-022-06158-w∟. PMID: 35606674∟. Observational study. ˍ

Teng C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S, Li X.
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Front Immunol. 2022 May 23;13:899710∟. doi: 10.3389/fimmu.2022.899710∟. PMID: 35677036∟. Observational study. ˍ

Xiong W, Li C, Kong G, Wan B, Wang S, Fan J.
Glioblastoma: two immune subtypes under the surface of the cold tumor.
Aging (Albany NY). 2022 May 23;14(10):4357-4375∟. doi: 10.18632/aging.204067∟. PMID: 35609054∟. Laboratory investigation. ˍ

*

Ustjanzew A, Sencio V, Trottein F, Faber J, Sandhoff R, Paret C.
Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance.
Int J Mol Sci. 2022 May 24;23(11):5896∟. doi: 10.3390/ijms23115896∟. PMID: 35682578∟. Laboratory investigation. ˍ

de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
Neuro Oncol. 2022 May 25:noac139∟. doi: 10.1093/neuonc/noac139∟. PMID: 35639513∟. Interventional study. ˍ

Klingenschmid J, Krigers A, Kerschbaumer J, Thomé C, Pinggera D, Freyschlag CF.
Surgical Management of Malignant Glioma in the Elderly.
Front Oncol. 2022 May 26;12:900382∟. doi: 10.3389/fonc.2022.900382∟. PMID: 35692808∟. Observational study. ˍ

Kraus RD, Weil CR, Frances Su FC, Cannon DM, Burt LM, Mendez JS.
Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients.
Neurooncol Pract. 2022 May 26;9(5):380-389∟. doi: 10.1093/nop/npac044∟. PMID: 36134015∟. Observational study. ˍ

Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik AD, Epari S, Jadhav M, Pathak S, Peelay Z, Walavalkar R, Muthuluri HK, Ravi Krishna M, Chandrasekharan A, Pande N, Gupta T, Banavali S, Jalali R.
Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.
EClinicalMedicine. 2022 May 26;49:101449∟. doi: 10.1016/j.eclinm.2022.101449∟. PMID: 35747192∟. Interventional study. ˍ

Di L, Shah AH, Mahavadi A, Eichberg DG, Reddy R, Sanjurjo AD, Morell AA, Lu VM, Ampie L, Luther EM, Komotar RJ, Ivan ME.
Radical supramaximal resection for newly diagnosed left-sided eloquent glioblastoma: safety and improved survival over gross-total resection.
J Neurosurg. 2022 May 27, 2022:1-8∟. doi: 10.3171/2022.3.JNS212399∟. PMID: 35623362∟. Observational study˰ ˍ

Weiss Lucas C, Faymonville AM, Loução R, Schroeter C, Nettekoven C, Oros-Peusquens AM, Langen KJ, Shah NJ, Stoffels G, Neuschmelting V, Blau T, Neuschmelting H, Hellmich M, Kocher M, Grefkes C, Goldbrunner R.
Surgery of Motor Eloquent Glioblastoma Guided by TMS-Informed Tractography: Driving Resection Completeness Towards Prolonged Survival.
Front Oncol. 2022 May 27;12:874631∟. doi: 10.3389/fonc.2022.874631∟. PMID: 35692752∟. Observational study. ˍ

Zapata Laguado M, Baez JM, Luna A, Mantilla C, Palencia M.
Bone Metastasis From Glioblastoma Multiforme: A Case Report.
Cureus. 2022 May 29;14(5):e25464∟. doi: 10.7759/cureus.25464∟. PMID: 35800795∟. Case report. ˍ

Oberheim-Bush NA, Shi W, McDermott MW, Grote A, Stindl J, Lustgarten L.
The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
J Neurooncol. 2022 May 31∟. doi: 10.1007/s11060-022-04033-4∟. PMID: 35639236∟. Observational study˰ ˍ

Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW; GLASS Consortium.
Glioma progression is shaped by genetic evolution and microenvironment interactions.
Cell. 2022 May 31;185(12):2184-2199.e16∟. doi: 10.1016/j.cell.2022.04.038∟. PMID: 35649412∟. Laboratory investigation˰ ˍ

Villani V, Prosperini L, Lecce M, Tanzilli A, Farneti A, Benincasa D, Telera S, Marucci L, Piludu F, Pace A.
Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit "Regina Elena" National Cancer Institute.
Neurol Sci. 2022 May 31∟. doi: 10.1007/s10072-022-06172-y∟. PMID: 35641731∟. Observational study˰ ˍ